Dr. Ronald Rodriguez received his B.S. degree in Life Sciences from the Massachusetts Institute of Technology (MIT) in 1984. He obtained his Ph.D. in Cell Biology from Baylor College of Medicine in 1990, and his M.D. from Baylor College of Medicine in 1992 as part of the Medical Scientist Training Program. After medical school, Dr. Rodriguez entered Johns Hopkins University School of Medicine in 1992 and completed his residency and fellowship training in 1998. He subsequently stayed on the faculty at Johns Hopkins from 1999-2012. During his last seven years at Johns Hopkins, he was the program director for urology training. In January 2013, he left Johns Hopkins to become the Henry B. and Edna Smith Dielmann Memorial Professor of Urologic Science, and the Chairman of the Department of Urology. Currently, he is the interim dean of the School of Medicine, UT Health. His vision for the institution is to have a strong basic science foundation which interacts and supports the clinical enterprise. As a native of San Antonio, he has a strong interest in outreach to the community and serving the minority population so prevalent in this part of the country.
M.D., Baylor College of Medicine (1992)
Ph.D., Baylor College of Medicine (1990)
B.S., Massachusetts Institute of Technology (1984)
John Hopkins Hospital, Fellowship, Urologic Oncology (1999)
John Hopkins Hospital, Residency, Urology (1998)
Johns Hopkins Hospital, Internship, Surgery (1993)
Dr. Rodriguez’s research interest has been in the translational realm. His research group is internationally recognized in the development of adenoviral gene therapy for urologic malignancies. He pioneered the first recombinant oncolytic adenovirus targeted for specific cancer and has been a leader in adenoviral gene therapy for 15 years. He developed the largest series of cryoablation for renal masses in the country and has made major contributions in molecular endocrinology, molecular imaging, outcomes from cancer research, and translational research. His group conducts basic science and translational research in a variety of urologic conditions. In spite of his administrative responsibilities he continues to oversee a basic research group and has a clinical practice focused on urologic cancer.